Diamyd Medical AB (publ) (DYMDF) Discusses Surprising Futility Results in Phase III Trial of Retogatein for Type 1 Diabetes Transcript

PresentationMaria Karlsson OsipovaDNB Carnegie Commissioned research Hello, and welcome to DNB Carnegie. My name is Maria Karlsson Osipova, and I'm a health care analyst here at the bank. Today with me in studio, I have Ulf Hannelius, CEO of Diamyd Medical, and we also have Dr. Joshua Vieth, Senior Director of Research at Breakthrough T1D and Mark Atkinson, Board member of Diamyd Medical, a PhD and Professor of Diabetes Research at Florida, University of Florida. As you can guess, we're going to talk about ...